A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
Overview
- Phase
- Phase 3
- Intervention
- Entecavir and or adefovir dipivoxil
- Conditions
- Hepatitis B, Chronic
- Sponsor
- Tongji Hospital
- Enrollment
- 300
- Locations
- 4
- Primary Endpoint
- Percentage of HBsAg loss at week 96
- Last Updated
- 9 years ago
Overview
Brief Summary
This study is a multi-center, randomized, prospective, open-label Phase III Clinical trial to assess the efficacy and safety of combination and sequential treatment with Y peginterferon Alfa-2b,entecavir and GMCSF in chronic hepatitis B patients nucleotides or nucleosides experienced. Patients were randomized to one of 3 groups to receive different antiviral treatment.
Detailed Description
Patients who have been pretreated with and responded to one or two nucleotides or nucleosides for at least one year, with HBV (Hepatitis B Virus) DNA less than 1000 copies/ml and HBsAg less 3000 IU/ml were randomized to one of 3 groups, to receive Y peginterferon Alfa-2b 180mcg/week for 96 weeks, entecavir 0.5 mg po daily for 48 weeks plus GMCSF (Granulocyte-macrophage colony stimulating factor) for 48 weeks, or Y peginterferon Alfa-2b 180mcg/week for 96 weeks and entecavir 0.5 mg po daily for 48 weeks, or only ETV for 96 weeks.
Investigators
Qin Ning
Director and Chair of Department of Infectious Diseases
Tongji Hospital
Eligibility Criteria
Inclusion Criteria
- •Male and female patients from 18 to 65 years of age;
- •HBsAg positive, entecavir and or adefovir dipivoxil are used at least 1 year including patients with nucleotides or nucleoside resistance history if their HBV DNA obtained control;
- •Before nucleotides or nucleosides treatment, ALT \> 2 ULN, HBV DNA \>10000 copies/ml,HBsAg positive;
- •Serum HBV DNA \< 1000 copies/ml;
- •Serum HBsAg \< 3000 IU/ml;
- •HBsAg positive;
- •Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug;
- •Absence of cirrhosis confirmed by ultrasonic test;
- •Agree to participate in the study and sign the patient informed consent.
Exclusion Criteria
- •Patients who had NAs resistance and HBV DNA \> 1000 copies/ml, or treatment of drugs with IFN longer than 6 months;
- •Other antiviral, anti-neoplastic or immunomodulatory treatment (including supra physiologic doses of steroids and radiation) 6 months prior to the first dose of randomized treatment (except for 7 days of acyclovir for herpetic lesions more than 1 month prior to first administration of randomized treatment). Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation are also excluded;
- •Women with ongoing pregnancy or breast-feeding;
- •Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which have the ability to do the test will do) and/or human immunodeficiency virus (HIV);
- •ALT \>10 ULN;
- •Evidence of decompensated liver disease (Child-Pugh score \> 5 ). Child-Pugh \> 5 means, if one of the following 5 conditions are met, the patient has to be excluded:
- •one of the following 5 conditions are met, the patient has to be excluded:
- •Serum albumin \< 3.5 g/L;
- •Prothrombin time \> 3 seconds prolonged;
- •Serum bilirubin \> 34 µ mol/L;
Arms & Interventions
1,conventional control group
Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
Intervention: Entecavir and or adefovir dipivoxil
2，combination and sequential group
Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
Intervention: Y peginterferon alfa-2b
2，combination and sequential group
Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
Intervention: Entecavir and or adefovir dipivoxil
3, multitarget group
Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
Intervention: Y peginterferon alfa-2b
3, multitarget group
Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
Intervention: Granulocyte-macrophage colony stimulating factor
3, multitarget group
Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
Intervention: Entecavir and or adefovir dipivoxil
Outcomes
Primary Outcomes
Percentage of HBsAg loss at week 96
Time Frame: week 96
Change from baseline in Percentage of HBsAg loss at week 96
Secondary Outcomes
- Change from baseline in HBsAg quantification and HBsAg decline at week 96(week 96)
- Change from baseline in HBsAg seroconversion at week 96(week 96)